ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

05 9 2023 15:05:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Participate in Two Investor Conferences in September

30 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 8 2023 15:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

11 8 2023 06:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs

20 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

22 6 2023 15:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

02 6 2023 07:00:00 提供 Nasdaq GlobeNewswire